CXCR Antagonist

CXCR Antagonists (99):

Cat. No.	Product Name	Effect	Purity

HY-114244

USL311	Antagonist	99.97%
USL311 is a potent and selective CXCR4 antagonist, with anti-tumor activity. USL311 prevents the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4.

HY-16509

UNBS5162	Antagonist	98.10%
UNBS5162 is a pan-antagonist of CXCL chemokine expression, with anti-tumor activity.

HY-119259

AZD8309	Antagonist	99.98%
AZD8309 is an orally active antagonist of CXCR2. AZD8309 has the ability to regulate the transmigration of neutrophils. AZD8309 can be used in the study of inflammatory diseases.

HY-151096

ACT-660602	Antagonist	99.86%
ACT-660602 is an orally active antagonist of chemokine receptor (CXCR3) with an IC₅₀ value of 204 nM. ACT-660602 inhibits T-cell migration and shows efficacy in acute lung ingury model. ACT-660602 can be used for autoimmune diseases research.

HY-103009

MSX-127	Antagonist	99.68%
MSX-127 is a CXCR4 antagonist. MSX-127 inhibits cancer metastasis.

HY-13021

SRT3190	Antagonist	99.77%
SRT3190 is an antagonist of CXCR2, used in the research of chemokine mediated diseases.

HY-P10415

EPI-X4	Antagonist	99.21%
EPI-X4 (hSA408–423 peptide) is an antagonist for C-X-C motif chemokine receptor 4 (CXCR4) with IC₅₀ of 8.6 μM. EPI-X4 blocks the CXCL12-mediated signaling, inhibits chemokine-mediated migration and invasion of leukemia cell. EPI-X4 exhibits anti-inflammatory activity in mouse model. EPI-X4 exhibits antiviral activity against CXCR4-tropic HIV with IC₅₀ of 8.6 μM.

HY-15319B

AMG 487 (S-enantiomer)	Antagonist	99.94%
AMG 487 S-enantiomer is the S enantiomer of AMG 487. AMG 487 is an antagonist of the chemokine receptor CXCR3.

HY-145640

Vimnerixin	Antagonist	99.39%
Vimnerixin (AZD4721) is the potent and orally active antagonist of acidic CXC chemokine receptor 2 (CXCR2). Vimnerixin has the potential for the research of inflammatory disease.

HY-16981

SB-332235	Antagonist	98.7%
SB-332235 is a potent, orally active nonpeptide CXCR2 antagonist, with an IC₅₀ of 7.7 nM. SB-332235 displays 285-fold selectivity for CXCR2 over CXCR1. SB-332235 inhibits acute and chronic models of arthritis in the rabbit. SB-332235 inhibits viability of AML cells.

HY-128063

CXCR3 antagonist 1	Antagonist	98.40%
CXCR3 antagonist 1 (compound 6c) is a selective and non-cytotoxic CXCR3 antagonist (IC₅₀=0.06 µM). CXCR3 antagonist 1 has potential in researching inflammatory diseases (including inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, and diabetes).

HY-139873

CXCR2 antagonist 2	Antagonist	99.12%
CXCR2 antagonist 2 is a potent CXCR2 antagonist for cancer immunoresearch with an IC₅₀ value of 95 nM.

HY-50101C

Mavorixafor hydrochloride	Antagonist	99.10%
Mavorixafor (AMD-070) hydrochloride is a potent, selective and orally available CXCR4 antagonist, with an IC₅₀ value of 13 nM against CXCR4 ¹²⁵I-SDF binding. Mavorixafor hydrochloride also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC₅₀ of 1 nM and 9 nM, respectively. Mavorixafor hydrochloride can be used for the study of WHIM syndrome.

HY-18263A

Elubrixin	Antagonist
Elubrixin (SB-656933) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin inhibits neutrophil CD11b upregulation (IC₅₀ of 260.7 nM) and shape change (IC₅₀ of 310.5 nM). Elubrixin has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation.

HY-120878A

(R,R)-CXCR2-IN-2	Antagonist	99.37%
(R,R)-CXCR2-IN-2, diastereoisomer of CXCR2-IN-2 (compound 68), is a brain penetrant CXCR2 antagonist with a pIC₅₀ of 9 and 6.8 in the Tango assay and d in the HWB Gro-α induced CD11b expression assay, respectively.

HY-101458

IT1t	Antagonist
IT1t is a potent CXCR4 antagonist; inhibits CXCL12/CXCR4 interaction with an IC₅₀ of 2.1 nM.

HY-P4111

Peptide R	Antagonist
Peptide R, a cyclic peptide, is a specific CXCR4 antagonist. Peptide R shows outstanding capacities to profoundly remodel the tumor stroma. Peptide R has the potential for tumor research.

HY-50101

Mavorixafor	Antagonist
Mavorixafor (AMD-070) is a potent, selective and orally available CXCR4 antagonist, with an IC₅₀ value of 13 nM against CXCR4 ¹²⁵I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC₅₀ of 1 and 9 nM, respectively. Mavorixafor can be used for the study of WHIM syndrome.

HY-103010

MSX-130	Antagonist	98.00%
MSX-130 is a CXCR4 antagonist. MSX-130 inhibits cancer metastasis.

HY-122058A

KRH-3955 hydrochloride	Antagonist
KRH-3955 hydrochloride is an orally bioavailable CXCR4 antagonist. KRH-3955 hydrochloride inhibits SDF-1α binding to CXCR4 with an IC₅₀ of 0.61 nM. KRH-3955 hydrochloride is also a highly potent and selective inhibitor of X4 HIV-1, with an EC₅₀ of 0.3 to 1.0 nM.

Name
Email *

	Sorry, but the email address you supplied was invalid.